Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002684 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00002684: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00002684 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002684, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as cisplatin, ifosfamide, and paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more tumor cells. PURPOSE: This phase II trial is studying how well combination chemotherapy works in treating patients with metastatic urinary tract cancer that cannot be treated with surgery.
Interventions
- DRUG cisplatin
- DRUG paclitaxel
- DRUG ifosfamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 1995-05 |
| Est. Completion | 2007-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002684
The ClinicalTrials.gov registry entry for NCT00002684 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.
NCT00002684 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002684 about?
NCT00002684 is a clinical study titled "Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer". RATIONALE: Drugs used in chemotherapy, such as cisplatin, ifosfamide, and paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more tumor cells. PURPOSE: This phase II trial is studying...
What is the current status of trial NCT00002684?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 1995-05. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00002684?
The interventions under investigation include: cisplatin (DRUG), paclitaxel (DRUG), ifosfamide (DRUG).
Who is sponsoring clinical trial NCT00002684?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.